添付文書からみた承認時と再審査終了時における副作用発現率の比較
スポンサーリンク
概要
- 論文の詳細を見る
Among various sources of information on ethical drugs, many medical personnel refer to the "package insert" in many occasions because of its reliability and availability. Every new drug is subject to "re-examination" usually after 8 years of marketing approval, in which its efficacy and safety are reexamined based on data obtained from post-marketing studies and others. The package insert is usually revised based on the result of re-examination and the revised insert contains information on adverse drug reactions reported both in clinical trials for marketing approval and post-marketing studies. Therefore the revision may be considered to be a major milestone, which provides a general idea of the safety profile of a new drug at marketing approval as well as after being on the market. In the present study, we compared adverse drug reaction rates at the time of new drug approval and at re-examination based on the revised package inserts to which safety information from postmarketing studies was added. The result showed that the rate of adverse drug reactions at re-examination had decreased compared to that at marketing approval for most of the new drugs investigated. In recent years, more and more new drugs are approved with less domestic clinical trial data. Therefore, pharmacists, as specialists on pharmaceuticals, are expected to understand correctly and provide safety information on pharmaceuticals based on proper understanding of the background of new drug development and not solely confined to the figures in the package inserts.(Jpn J Clin Pharmacol Ther 2013; 44(6): 463-468)
- 一般社団法人 日本臨床薬理学会の論文
一般社団法人 日本臨床薬理学会 | 論文
- 臨床家の立場より : 脳循環代謝改善薬
- 生体肝移植ならびに小腸移植術後のタクロリムス投与方法
- 甲状腺機能低下によりWarfarin効果の減弱がみられた症例
- 治験の品質管理における治験コーデイネーターの役割
- 治験,臨床試験,臨床研究とCRC